Rimegepant. calcitonin gene-related peptide (CGRP) receptor antagonist, treatment of migraine

Rimegepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under development by Biohaven Pharmaceuticals for the acute and preventive treatment of migraine. Among patients with acute migraine, significant clinical efficacy has been reported with a rimegepant single dose. The completed pivotal phase II and III trials showed a beneficial action of rimegepant in terms of pain freedom, pain relief, release of migraine symptoms and lifestyle recovery. Moreover, adverse events were mild or moderate and did not cause trial discontinuation. Several clinical trials are currently ongoing to evaluate long-term safety and efficacy profiles in patients with migraine and refractory trigeminal neuralgia. Drug–drug interactions potentially affecting rimegepant pharmacokinetics should be assessed in future clinical trials.